Disruption of the pain receptor transient receptor potential vanilloid 1 can affect mortality, blood bacteria clearance and cytokine response in sepsis, according to a study published in ...

XEN-D0501, a transient receptor potential vanilloid 1 (TRPV1) antagonist, is gaining attention for its potential as an oral tablet to treat type 2 diabetes, obesity, and cardiovascular diseases. Dorte ...

Touch a hot plate and your hand flies back. While the response is almost instant, researchers are still working to better understand the molecular mechanisms behind these sensations of heat and pain.

“The most provocative data is just the longevity,” said Gerard Ahern of Georgetown University, noting that the connection between TRPV1 and lifespan is “very novel and perhaps unexpected.” Ahern was ...

SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company developing novel, non-opioid pain therapeutics, today announced publication of a multicenter, ...